<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585180</url>
  </required_header>
  <id_info>
    <org_study_id>CHD 052-15</org_study_id>
    <nct_id>NCT02585180</nct_id>
  </id_info>
  <brief_title>Subglottic Secretions Surveillance to Predict Bacterial Pathogens Involved in Ventilator-associated Pneumonia</brief_title>
  <official_title>Subglottic Secretions Surveillance to Predict Bacterial Pathogens Involved in Ventilator-associated Pneumonia (VAP): an Ancillary Study of the DEMETER Trial (NCT02515617)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many studies provide evidence for the benefit of lower respiratory tract surveillance, mostly&#xD;
      by culture of endotracheal secretions, to predict bacterial pathogens (especially multi-drugs&#xD;
      resistant pathogens) involved in VAP. The DEMETER study (NCT02515617) assessing the&#xD;
      medico-economical impact of the subglottic secretions drainage (SSD) provides the opportunity&#xD;
      to evaluate the accuracy of the subglottic secretions culture surveillance to predict&#xD;
      pathogens involved in VAP (in comparison with the concomitant endotracheal secretions&#xD;
      surveillance). These subglottic and tracheal secretions culture surveillance will be masked&#xD;
      to the investigators of the DEMETER Study.&#xD;
&#xD;
      This ancillary study will be performed in 14 centers participating to the DEMETER study&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2015</start_date>
  <completion_date type="Actual">November 29, 2017</completion_date>
  <primary_completion_date type="Actual">November 29, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of adjudicated VAP in which the bacteria involved have been, previously, detected with the subglottic secretions culture surveillance.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
    <description>For each episode of VAP, bacteria involved will be compared with bacteria isolated, previously, into the subglottic secretions. This comparison will be performed by the microbiologist of each center. A bacteria isolated into the subglottic secretions will be considered as the same than the one involved in VAP if these 2 same micro-organisms have the same antibiotics susceptibility. Moreover, for the comparison, the third last subglottic secretions samples, if available, obtained before the VAP occurrence, will be taking account.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of adjudicated VAP in which the bacteria involved have been, previously, detected with the tracheal secretions culture surveillance.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
    <description>For each episode of VAP, bacteria involved will be compared with bacteria isolated, previously, into the tracheal secretions. This comparison will be performed by the microbiologist of each center. A bacteria isolated into the tracheal secretions will be considered as the same than the one involved in VAP if these 2 same microorganisms have the same antibiotics susceptibility. Moreover, for the comparison, the third last tracheal secretions samples, if available, obtained before the VAP occurrence will be taking account.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate probabilistic antibiotherapy initiated during the study by the investigators in case of adjudicated VAP</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
    <description>Proportion of VAP for whom the probabilistic antibiotherapy used during the trial appeared to be empirically active</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate theoretical probabilistic antibiotherapy with the knowledge of the subglottic culture surveillance</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
    <description>Proportion of adjudicated VAP for whom a theoretical probabilistic antibiotherapy would be empirically active with the knowledge of the results of the subglottic secretions samples obtained more than 3 days before the occurrence of VAP. The theoretical antibiotherapy will be determined by an independent committee unaware of the type of samples evaluated (subglottic or tracheal secretions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate theoretical probabilistic antibiotherapy with the knowledge of the tracheal culture surveillance</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
    <description>Proportion of adjudicated VAP for whom a theoretical probabilistic antibiotherapy would be empirically active with the knowledge of the results of the tracheal secretions samples obtained more than 3 days before the occurrence of VAP. The theoretical antibiotherapy will be determined by an independent committee unaware of the type of samples evaluated (subglottic or tracheal secretions).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Ventilator-associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Period with endotracheal tubes not allowing SSD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period with endotracheal tubes allowing SSD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endotracheal tubes not allowing SSD</intervention_name>
    <description>In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure</description>
    <arm_group_label>Period with endotracheal tubes not allowing SSD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endotracheal tubes allowing SSD</intervention_name>
    <description>In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.&#xD;
In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours.</description>
    <arm_group_label>Period with endotracheal tubes allowing SSD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  Invasive mechanical ventilation delivered via an endotracheal tube and expected to be&#xD;
             required more than 24 hours&#xD;
&#xD;
          -  Intubation performed in units in which the specific endotracheal tube allowing the&#xD;
             subglottic secretions drainage will be available during the SSD period of the trial&#xD;
&#xD;
          -  Information delivered&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous inclusion in the study&#xD;
&#xD;
          -  Patients moribund at the Intensive Care Unit admission&#xD;
&#xD;
          -  Pregnant, parturient or breast-feeding woman&#xD;
&#xD;
          -  Patient hospitalized without consent and/or deprived of liberty by court's decision&#xD;
&#xD;
          -  Patient under guardianship or curators&#xD;
&#xD;
          -  Lack of social insurance&#xD;
&#xD;
          -  Concomitant inclusion in a trial on VAP prevention&#xD;
&#xD;
          -  Patient with no comprehension of the French language&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude LACHERADE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD VENDEE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU André Vésale</name>
      <address>
        <city>Montigny-le-Tilleul.</city>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Annecy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal des Portes de l'Oise</name>
      <address>
        <city>Beaumont-sur-Oise</city>
        <zip>95260</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chd Vendee</name>
      <address>
        <city>La roche sur yon</city>
        <zip>85170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Docteur Schaffner</name>
      <address>
        <city>Lens</city>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Montauban</name>
      <address>
        <city>Montauban</city>
        <zip>82013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional d'Orléans</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pointe à Pitre les Abymes</name>
      <address>
        <city>Pointe-à-Pitre</city>
        <zip>97159</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Poissy Saint Germain</name>
      <address>
        <city>Poissy</city>
        <zip>78600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Dubos</name>
      <address>
        <city>Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Saint Nazaire</name>
      <address>
        <city>Saint Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Réunion, site de Saint Denis de la Réunion</name>
      <address>
        <city>Saint-Denis (Réunion)</city>
        <zip>97405</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours, site Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Brusselaers N, Labeau S, Vogelaers D, Blot S. Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: systematic review and diagnostic test accuracy meta-analysis. Intensive Care Med. 2013 Mar;39(3):365-75. doi: 10.1007/s00134-012-2759-x. Epub 2012 Nov 28. Review.</citation>
    <PMID>23188467</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventilator-associated pneumonia</keyword>
  <keyword>Surveillance</keyword>
  <keyword>Subglottic-secretions</keyword>
  <keyword>Critically ill patients</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silver Sulfadiazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

